Idenix Pharmaceuticals (NASDAQ: IDIX) was downgraded by Stifel Nicolaus to a “sell” rating in a research note issued on Friday.
Separately, analysts at JMP Securities downgraded shares of Idenix Pharmaceuticals from a “market perform” rating to an “underperform” rating in a research note to investors on Monday, January 9th. Analysts at Bank of America (NYSE: BAC) raised their price target on shares of Idenix Pharmaceuticals to $18.00 in a research note to investors on Monday, January 9th. Also, analysts at Brean Murray reiterated a “sell” rating on shares of Idenix Pharmaceuticals in a research note to investors on Friday, December 23rd.
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company’s research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).
Shares of Idenix Pharmaceuticals opened at 14.33 on Friday. Idenix Pharmaceuticals has a one year low of $2.67 and a one year high of $15.25. The stock’s 50-day moving average is $9.92 and its 200-day moving average is $6.85. The company’s market cap is $1.378 billion.